{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:44:36Z","timestamp":1761237876035},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.clinthera.2012.01.002","type":"journal-article","created":{"date-parts":[[2012,2,10]],"date-time":"2012-02-10T22:47:18Z","timestamp":1328914038000},"page":"351-362.e3","source":"Crossref","is-referenced-by-count":15,"title":["Evaluation of Gabapentin Enacarbil on Cardiac Repolarization: A Randomized, Double-Blind, Placebo- and Active-Controlled, Crossover Thorough QT\/QTc Study in Healthy Adults"],"prefix":"10.1016","volume":"34","author":[{"given":"Dan","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritu","family":"Lal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Zomorodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harisha","family":"Atluri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judy","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Tovera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Bonzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Cundy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2012.01.002_bib2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.4065\/mcp.2009.0700","article-title":"Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study","volume":"85","author":"Bogan","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clinthera.2012.01.002_bib3","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1212\/01.wnl.0000341770.91926.cc","article-title":"Randomized, double-blind, placebo-controlled trial of XP13512\/GSK1838262 in patients with RLS","volume":"72","author":"Kushida","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2012.01.002_bib4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/sleep\/32.2.159","article-title":"A randomized, double-blind, placebo-controlled, crossover study of XP13512\/GSK1838262 in the treatment of patients with primary restless legs syndrome","volume":"32","author":"Kushida","year":"2009","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2012.01.002_bib5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/WNF.0b013e3181b3ab16","article-title":"Gabapentin enacarbil in restless legs syndrome: A phase 2b, two-week, randomized, double-blind, placebo-controlled trial","volume":"32","author":"Walters","year":"2009","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.clinthera.2012.01.002_bib6","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3390\/jcm7090282","article-title":"A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome","volume":"7","author":"Lee","year":"2011","journal-title":"J Clin Sleep Med"},{"key":"10.1016\/j.clinthera.2012.01.002_bib7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/WNF.0b013e3182087d48","article-title":"A 52-week study of gabapentin enacarbil in restless legs syndrome","volume":"34","author":"Ellenbogen","year":"2011","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.clinthera.2012.01.002_bib9","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/j.1528-1157.1997.tb01223.x","article-title":"Failure of absorption of gabapentin after rectal administration","volume":"38","author":"Kriel","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinthera.2012.01.002_bib10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1528-1157.1997.tb01078.x","article-title":"Colonic absorption of antiepileptic agents","volume":"38","author":"Stevenson","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinthera.2012.01.002_bib11","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1177\/0091270008322909","article-title":"Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin","volume":"48","author":"Cundy","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.01.002_bib12","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1023\/A:1018951214146","article-title":"A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma","volume":"10","author":"Stewart","year":"1993","journal-title":"Pharm Res"},{"key":"10.1016\/j.clinthera.2012.01.002_bib13","article-title":"Multiple-dose, dose-proportionality study of Neurontin (gabapentin) in healthy volunteers","volume":"37","author":"Bockbrader","year":"1996","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinthera.2012.01.002_bib14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0920-1211(98)00020-5","article-title":"Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy","volume":"31","author":"Gidal","year":"1998","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.clinthera.2012.01.002_bib15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-1211(00)00117-0","article-title":"Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability","volume":"40","author":"Gidal","year":"2000","journal-title":"Epilepsy Res"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2012.01.002_bib16","first-page":"S17","article-title":"Clinical pharmacokinetics of gabapentin","volume":"44","author":"McLean","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2012.01.002_bib17","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1124\/jpet.104.067959","article-title":"XP13512 [(\u00b1)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II","volume":"311","author":"Cundy","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2012.01.002_bib18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/jpet.104.067934","article-title":"XP13512 [(\u00b1)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I","volume":"311","author":"Cundy","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2012.01.002_bib19","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.clinthera.2009.07.026","article-title":"Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled, crossover study in healthy volunteers","volume":"31","author":"Lal","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2012.01.002_bib20","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/0002-9149(92)90562-D","article-title":"An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study)","volume":"70","author":"Sagie","year":"1992","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2012.01.002_bib23","series-title":"Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects: 2004 Revision","year":"2004"},{"key":"10.1016\/j.clinthera.2012.01.002_bib24","series-title":"Design and Analysis of Bioavailability and Bioequivalence Studies","first-page":"31","article-title":"Designs of bioavailability studies","author":"Chow","year":"2000"},{"key":"10.1016\/j.clinthera.2012.01.002_bib25","series-title":"Pharmacokinetics","author":"Gibaldi","year":"1982"},{"key":"10.1016\/j.clinthera.2012.01.002_bib26","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/sim.4780111304","article-title":"Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design","volume":"11","author":"Frison","year":"1992","journal-title":"Stat Med"},{"key":"10.1016\/j.clinthera.2012.01.002_bib27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/0091270007307881","article-title":"Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review","volume":"48","author":"Garnett","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.01.002_bib28","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.ajem.2006.03.011","article-title":"Cardiac conduction disturbances after an overdose of nefazodone and gabapentin","volume":"24","author":"Rasimas","year":"2006","journal-title":"Am J Emerg Med"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2012.01.002_bib29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00003088-200140001-00003","article-title":"Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers","volume":"40","author":"Lettieri","year":"2001","journal-title":"Clin Pharmacokinet"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812000033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812000033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,23]],"date-time":"2019-06-23T14:41:04Z","timestamp":1561300864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291812000033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0149291812000033"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.01.002","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}